Lacosamide Vivanta

Lacosamide, the active ingredient in Lacosamide Vivanta, is an anti‑epileptic presented as an intravenous formulation for use in patients with partial‑onset seizures and epilepsy. It works by modulating neuronal sodium channels to reduce hyperexcitability.

GNH USA supplies Lacosamide Vivanta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing reliable sourcing for clinical and procurement teams across multiple regions while adhering to stringent quality standards and regulatory requirements.

Lacosamide is an anti‑epileptic drug indicated for conditions within the seizure disorder family.

Partial‑onset seizures: reduces seizure frequency as adjunctive therapy. Epilepsy: contributes to overall seizure control in patients with focal epilepsy. Adjunctive therapy for refractory focal seizures: provides additional seizure reduction when combined with other antiepileptic medications.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Cardiac arrhythmia (e.g., PR‑interval prolongation) - Atrial fibrillation - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal ideation or behavior - Hepatic dysfunction - Severe hypotension

When prescribing Lacosamide, clinicians should consider several safety measures.

Cardiac monitoring: observe ECG for PR‑interval prolongation. Renal function: adjust dosing in severe renal impairment. Hepatic function: assess liver enzymes before initiation. Hypersensitivity: discontinue if rash or angioedema occurs. Abrupt discontinuation: taper to avoid seizure worsening. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inducers (e.g., carbamazepine) may reduce efficacy. - Co‑administration with other sodium‑channel blockers may increase risk of cardiac conduction effects. - Combination with drugs that prolong PR interval (e.g., beta‑blockers) may exacerbate cardiac effects.

Moderate Interactions (Monitor Closely): - Use with other antiepileptic drugs may require dose adjustments. - Concurrent use with anticoagulants may increase bleeding risk. - Combination with alcohol may enhance central nervous system depression.